The Ajarn Kasem Pangsriwong Foundation supported the research project;Pharmaceutical Care Training Center(PCTC)at the Faculty of Pharmacy,Chiang Mai University。
Background:The patterns of dual antiplatelet therapy(DAPT)use and the associated clinical outcomes in current practice remain limited.This study evaluates DAPT regimen patterns and clinical outcomes among acute corona...
The authors report the first case of thrombolysis in a patient already receiving both aspirin and prasugrel following a recent ischemic coronary event. A 55-year-old gentleman was treated for inferior wall myocardial ...
Antiplatelet therapy is the cornerstone of the therapeutic arsenal in coronary artery disease.Thanks to a better understanding in physiology,pharmacology and pharmacogenomics huge progress were made in the field of pl...
Antiplatelet therapy with aspirin or clopidogrel or both is the standard care for patients with proven coronary or peripheral arterial disease,especially those undergoing endovascular revascularization procedures. How...
Aim To evaluate the time-effect and dose-effect of prasugrel hydrobromide acetic acid compound (PHAAC) inhibiting platelet aggregation. Methods For the time-effect study, 190 Sprague-Dawley (SD) rats were devided ...
Aim: To characterize the pharmacokinetics (PKs), pharmacodynamics (PDs), and tolerability of different dose regimens of prasugrel in healthy Chinese subjects. Methods: This was a single-centered, open-label, par...
Supported by Project and Fellowship Grants from the National Health and Medical Research Council of Australia
AIM: To optimize the experimental protocols for a simple, sensitive and accurate bleeding assay.METHODS: Bleeding assay was performed in mice by tail tip amputation, immersing the tail in saline at 37 ℃, continuously...
Dual antiplatelet therapy consisting of low-dose aspirin (LDA) and other antiplatelet medications is recommended in patients with coronary heart disease, but it may increase the risk of esophageal lesion and bleeding....
Background Clopidogrel is beneficial after acute coronary syndrome. Recent studies suggest the superiority of prasugrel compared with clopidogrel. The enhanced platelet inhibition with prasugrel lead to a reduction in...
Clopidogrel is a mainstay in the treatment of patients with acute coronary syndromes or those receiving endovascular prostheses.However,its efficacy has been challenged in the recent past by studies suggesting variabl...